{"id":695304,"date":"2024-04-17T09:34:01","date_gmt":"2024-04-17T09:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=695304"},"modified":"2024-04-17T09:34:01","modified_gmt":"2024-04-17T09:34:01","slug":"guillainbarr-syndrome-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-chafic-karam-hansa-biopharma-ab-annexon","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/guillainbarr-syndrome-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-chafic-karam-hansa-biopharma-ab-annexon_695304.html","title":{"rendered":"Guillain-Barr\u00e9 Syndrome Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Chafic Karam, Hansa Biopharma AB, Annexon"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1713270309.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Guillain-Barr&eacute; Syndrome Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Chafic Karam, Hansa Biopharma AB, Annexon\" src=\"https:\/\/www.abnewswire.com\/uploads\/1713270309.jpeg\" alt=\"Guillain-Barr&eacute; Syndrome Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Chafic Karam, Hansa Biopharma AB, Annexon\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Guillain-Barr\u00e9 Syndrome Market Forecast report offers an in-depth understanding of the Guillain-Barr\u00e9 Syndrome, historical and forecasted epidemiology as well as the Guillain-Barr\u00e9 Syndrome market trends in the 7MM.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Guillain-Barr&eacute; Syndrome Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Guillain-Barr&eacute; Syndrome, historical and forecasted epidemiology as well as the Guillain-Barr&eacute; Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Guillain-Barr&eacute; Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Guillain-Barr&eacute; Syndrome Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Guillain-Barr&eacute; Syndrome Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Guillain-Barr&eacute; Syndrome market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period (2019-2032)<\/li>\n<li><strong>In December 2023, Hansa Biopharma,<\/strong> known as &#8220;Hansa,&#8221; released encouraging preliminary findings from the phase 2 trial 15-HMedIdeS-09, showcasing the safety and tolerability of imlifidase alongside standard care. The trial demonstrated swift enhancements in disease-related effectiveness measures. Further evaluation of the efficacy data is scheduled for 2024. The 15-HMedIdeS-09 trial, designed as an open-label, single-arm study, evaluates the safety, tolerance, and efficacy of imlifidase in patients with Guillain-Barr&eacute; Syndrome (GBS) in conjunction with standard intravenous immunoglobulin (IVIg) treatment.<\/li>\n<li><strong>In October 2023, Annexon, Inc. (Nasdaq: ANNX)<\/strong>, a clinical-stage biopharmaceutical firm specializing in novel complement-based therapies for autoimmune, neurodegenerative, and ophthalmic ailments, disclosed that the European Medicines Agency (EMA) has awarded orphan drug status to ANX005 for Guillain-Barr&eacute; Syndrome (GBS) treatment. Previously, the U.S. Food and Drug Administration (FDA) had also granted ANX005 orphan drug status for GBS treatment.<\/li>\n<li>As per the National Organization of Rare Disorders (NORD) (n.d.), Guillain-Barr&eacute; Syndrome (GBS) impacts approximately one to two individuals annually per 100,000 population. The precise cause of this condition remains uncertain. It&#8217;s noted that around half of those affected experience a gastrointestinal or respiratory infection in the days leading up to the onset of symptoms.<\/li>\n<li>The outlook for Guillain-Barr&eacute; Syndrome (GBS) varies depending on its specific form. While some patients achieve full recovery, others may still face challenges with walking six months after the onset of the disease. In severe cases, GBS can unfortunately lead to a fatal outcome.<\/li>\n<li><strong>Key Guillain-Barr&eacute; Syndrome Companies:<\/strong> Chafic Karam, Hansa Biopharma AB, Annexon, and others<\/li>\n<li><strong>Key Guillain-Barr&eacute; Syndrome Therapies:<\/strong> Efgartigimod Alfa-Fcab, Imlifidase, ANX005, and others<\/li>\n<li>The Guillain-Barr&eacute; Syndrome epidemiology based on gender analyzed that Guillain-Barr&eacute; Syndrome is more common in men than in women<\/li>\n<li>The Guillain-Barr&eacute; Syndrome market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Guillain-Barr&eacute; Syndrome pipeline products will significantly revolutionize the Guillain-Barr&eacute; Syndrome market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Guillain-Barr&eacute; Syndrome Overview <\/strong><\/p>\n<p style=\"text-align: justify;\">Guillain-Barr&eacute; Syndrome (GBS) is a rare neurological disorder where the body&#8217;s immune system mistakenly attacks its nerves. This condition leads to muscle weakness, numbness, and in some cases, paralysis. GBS often begins with tingling sensations and weakness in the legs, which can rapidly progress to affect the arms and upper body. In severe cases, GBS can cause paralysis of the entire body, including the muscles involved in breathing, requiring hospitalization and sometimes intensive care.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Guillain-Barr&eacute; Syndrome Market Forecast, Size &amp; Share Analysis Report:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/guillain-barre-syndrome-gbs-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Guillain-Barr&eacute; Syndrome Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Guillain-Barr&eacute; Syndrome Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Guillain-Barr&eacute; Syndrome market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Guillain-Barr&eacute; Syndrome<\/li>\n<li>Prevalent Cases of Guillain-Barr&eacute; Syndrome by severity<\/li>\n<li>Gender-specific Prevalence of Guillain-Barr&eacute; Syndrome<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Guillain-Barr&eacute; Syndrome<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Guillain-Barr&eacute; Syndrome epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Guillain-Barr&eacute; Syndrome Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Guillain-Barr&eacute; Syndrome Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Guillain-Barr&eacute; Syndrome market or expected to get launched during the study period. The analysis covers Guillain-Barr&eacute; Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Guillain-Barr&eacute; Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Guillain-Barr&eacute; Syndrome Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Efgartigimod Alfa-Fcab:<\/strong> Chafic Karam<\/li>\n<li><strong>Imlifidase:<\/strong> Hansa Biopharma AB<\/li>\n<li><strong>ANX005:<\/strong> Annexon, Inc.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Guillain-Barr&eacute; Syndrome market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Guillain-Barr&eacute; Syndrome Treatment Landscape<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Guillain-Barr&eacute; Syndrome Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Guillain-Barr&eacute; Syndrome Companies:<\/strong> Chafic Karam, Hansa Biopharma AB, Annexon, Inc., and others<\/li>\n<li><strong>Key Guillain-Barr&eacute; Syndrome Therapies:<\/strong> Efgartigimod Alfa-Fcab, Imlifidase, ANX005, and others<\/li>\n<li><strong>Guillain-Barr&eacute; Syndrome Therapeutic Assessment:<\/strong> Guillain-Barr&eacute; Syndrome current marketed and Guillain-Barr&eacute; Syndrome emerging therapies<\/li>\n<li><strong>Guillain-Barr&eacute; Syndrome Market Dynamics:<\/strong> Guillain-Barr&eacute; Syndrome market drivers and Guillain-Barr&eacute; Syndrome market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Guillain-Barr&eacute; Syndrome Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Guillain-Barr&eacute; Syndrome Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Guillain-Barr&eacute; Syndrome companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/guillain-barre-syndrome-gbs-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Guillain-Barr&eacute; Syndrome Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Guillain-Barr&eacute; Syndrome Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Guillain-Barr&eacute; Syndrome<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Guillain-Barr&eacute; Syndrome<\/p>\n<p style=\"text-align: justify;\">4. Guillain-Barr&eacute; Syndrome Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Guillain-Barr&eacute; Syndrome Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Guillain-Barr&eacute; Syndrome Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Guillain-Barr&eacute; Syndrome Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Guillain-Barr&eacute; Syndrome&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Guillain-Barr&eacute; Syndrome Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Guillain-Barr&eacute; Syndrome Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Guillain-Barr&eacute; Syndrome Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Guillain-Barr&eacute; Syndrome Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Guillain-Barr&eacute; Syndrome Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Guillain-Barr&eacute; Syndrome Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Guillain-Barr&eacute; Syndrome Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Guillain-Barr&eacute; Syndrome Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Guillain-Barr&eacute; Syndrome Appendix<\/p>\n<p style=\"text-align: justify;\">18. Guillain-Barr&eacute; Syndrome Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=guillainbarr-syndrome-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-chafic-karam-hansa-biopharma-ab-annexon\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=guillainbarr-syndrome-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-chafic-karam-hansa-biopharma-ab-annexon\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Guillain-Barr\u00e9 Syndrome Market Forecast report offers an in-depth understanding of the Guillain-Barr\u00e9 Syndrome, historical and forecasted epidemiology as well as the Guillain-Barr\u00e9 Syndrome market trends in the 7MM. DelveInsight&rsquo;s &ldquo;Guillain-Barr&eacute; Syndrome Market Insights, Epidemiology, and Market Forecast-2032&Prime; report offers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/guillainbarr-syndrome-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-chafic-karam-hansa-biopharma-ab-annexon_695304.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-695304","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/695304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=695304"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/695304\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=695304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=695304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=695304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}